(R)-(-)-2-Ethyltetrahydrofuran | 51769-31-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢呋喃
• 英文名称: (R)-(-)-2-Ethyltetrahydrofuran
• 英文别名: (2R)-2-ethyloxolane
• CAS: 51769-31-4
• 化学式: C₆H₁₂O
• 分子量: 100.161
• InChiKey: IHMXVSZXHFTOFN-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-(-)-2-Ethyltetrahydrofuran 在 四氧化钌 作用下， 以 四氯化碳 为溶剂， 以60%的产率得到4-hexanolide
  参考文献：
  名称：

  Dihydro- and Tetrahydrofuran Building Blocks from 1,4:3,6-Dianhydrohexitols. 2. Synthesis of Acetal, Alcohol, Diol, Epoxide, Hydrocarbon, and Lactone Pheromones

  摘要：

  The potential of building blocks 1-3 for synthesis of enantiopure substances is illustrated by their transformation to various insect pheromones featuring functionalities specified in the title. A convenient synthesis of building block 3 from sorbitol is described.

  DOI：

  10.1021/jo00106a030
• 作为产物：
  描述：

  (S)-(+)-2-<2-O-(p-Tolylsulfonyl)ethyl>tetrahydrofuran 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以90%的产率得到(R)-(-)-2-Ethyltetrahydrofuran
  参考文献：
  名称：

  Dihydro- and Tetrahydrofuran Building Blocks from 1,4:3,6-Dianhydrohexitols. 2. Synthesis of Acetal, Alcohol, Diol, Epoxide, Hydrocarbon, and Lactone Pheromones

  摘要：

  The potential of building blocks 1-3 for synthesis of enantiopure substances is illustrated by their transformation to various insect pheromones featuring functionalities specified in the title. A convenient synthesis of building block 3 from sorbitol is described.

  DOI：

  10.1021/jo00106a030

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• MONOCARBAMS
  申请人：Brickner Steven Joseph

  公开号：US20100160281A1

  公开（公告）日：2010-06-24

  The invention relates to compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of formula (I).

  这项发明涉及式(I)的化合物： 其中R1，R2，R3，R4，R5和R6如本文所定义。该发明还涉及使用式(I)的化合物治疗细菌感染的药物组合物和方法。
• [EN] 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE<br/>[FR] 2-OXO -3,4-DIHYDROPYRIDINE -5-CARBOXYLATES ET LEUR UTILISATION
  申请人：UNIV LILLE II DROIT & SANTE

  公开号：WO2016016238A1

  公开（公告）日：2016-02-04

  The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

  本发明涉及公式（I）的新化合物，其药用盐或溶剂和它们的用途。
• [EN] ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE SUBSTITUÉS PAR ALKYLE EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018093576A1

  公开（公告）日：2018-05-24

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.

  化合物I和化合物II，其药用可接受的盐，上述任何一个的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。化合物I和化合物II具有以下结构：(I)，(II)，其中变量的定义在此提供。